NASDAQ:ABVX ABIVAX Société Anonyme (ABVX) Stock Price, News & Analysis $12.35 +0.07 (+0.57%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$11.89▼$12.3850-Day Range$10.85▼$13.7552-Week Range$7.99▼$17.02Volume76,768 shsAverage Volume83,327 shsMarket Capitalization$777.17 millionP/E RatioN/ADividend YieldN/APrice Target$36.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get ABIVAX Société Anonyme alerts: Email Address ABIVAX Société Anonyme MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside195.5% Upside$36.50 Price TargetShort InterestHealthy0.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.98) to ($2.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.49 out of 5 starsMedical Sector540th out of 910 stocksPharmaceutical Preparations Industry249th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingABIVAX Société Anonyme has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageABIVAX Société Anonyme has only been the subject of 1 research reports in the past 90 days.Read more about ABIVAX Société Anonyme's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.30% of the float of ABIVAX Société Anonyme has been sold short.Short Interest Ratio / Days to CoverABIVAX Société Anonyme has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ABIVAX Société Anonyme has recently increased by 72.54%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldABIVAX Société Anonyme does not currently pay a dividend.Dividend GrowthABIVAX Société Anonyme does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABVX. Previous Next 1.1 News and Social Media Coverage Search Interest2 people have searched for ABVX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added ABIVAX Société Anonyme to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ABIVAX Société Anonyme insiders have not sold or bought any company stock.Percentage Held by Institutions47.91% of the stock of ABIVAX Société Anonyme is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ABIVAX Société Anonyme's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ABIVAX Société Anonyme are expected to grow in the coming year, from ($2.98) to ($2.90) per share.Price to Book Value per Share RatioABIVAX Société Anonyme has a P/B Ratio of 3.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> About ABIVAX Société Anonyme Stock (NASDAQ:ABVX)ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Read More ABVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABVX Stock News HeadlinesAugust 31, 2024 | americanbankingnews.comAnalysts Set ABIVAX Société Anonyme (NASDAQ:ABVX) PT at $36.50August 30, 2024 | americanbankingnews.comABIVAX Société Anonyme (NASDAQ:ABVX) Sees Significant Increase in Short InterestSeptember 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.August 21, 2024 | investing.comAbivax SA ADR (ABVX)August 6, 2024 | globenewswire.comAbivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment MilestoneJuly 15, 2024 | globenewswire.comAbivax Provides Operational and Key Program UpdateJune 4, 2024 | globenewswire.comAbivax releases the results of its May 30, 2024 Ordinary and Extraordinary General MeetingApril 10, 2024 | seekingalpha.comABIVAX Société Anonyme (AAVXF) Q4 2023 Earnings Call TranscriptSeptember 7, 2024 | Behind the Markets (Ad)⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.April 10, 2024 | seekingalpha.comABVX ABIVAX Société AnonymeApril 2, 2024 | globenewswire.comAbivax reports 2023 financial results and operational updateMarch 14, 2024 | morningstar.comAbivax SA ADR ABVXFebruary 23, 2024 | wsj.comAbivax S.A. ADRFebruary 20, 2024 | finance.yahoo.comABIVAX Société Anonyme (ABVX.PA)February 17, 2024 | morningstar.comAbivax SA ABVXFebruary 13, 2024 | finance.yahoo.comAbivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)January 29, 2024 | finance.yahoo.comAbivax Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq ListingJanuary 29, 2024 | finance.yahoo.comAbivax Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Price RangeSee More Headlines Receive ABVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ABIVAX Société Anonyme and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABVX Previous SymbolNASDAQ:ABVX CUSIPN/A CIK1956827 Webwww.abivax.com Phone33-1-53-83-09-63FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Stock Price Target$36.50 High Stock Price Target$50.00 Low Stock Price Target$16.00 Potential Upside/Downside+195.5%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.23 Current Ratio4.08 Quick Ratio4.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.37 per share Price / Book3.66Miscellaneous Outstanding Shares62,929,000Free FloatN/AMarket Cap$777.17 million OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Marc M. P. de Garidel M.B.A. (Age 66)CEO & Interim Chair of Board Comp: $862.25kDr. Philippe Pouletty M.D. (Age 66)Ph.D., Founder & Director Mr. Didier Blondel (Age 60)EVP, CFO & Board Secretary Mr. Didier Scherrer Ph.D. (Age 54)Chief Scientific Officer Mr. Patrick MalloySenior Vice President of Investor RelationsMs. Ida Hatoum (Age 49)Chief People Officer Mr. Pierre Courteille M.B.A. (Age 55)Chief Business Officer Mr. Jerome Denis Ph.D.Executive Vice President of Process Development & ManufacturingMr. Sheldon Sloan M.B.E. (Age 65)M.D., Chief Medical Officer Mr. Michael Ferguson B.S. (Age 46)M.B.A., Chief Commercial Officer More ExecutivesKey CompetitorsHUTCHMEDNASDAQ:HCMXenon PharmaceuticalsNASDAQ:XENESpringWorks TherapeuticsNASDAQ:SWTXMerusNASDAQ:MRUSRhythm PharmaceuticalsNASDAQ:RYTMView All CompetitorsInstitutional OwnershipNantahala Capital Management LLCSold 24,400 shares on 8/20/2024Ownership: 1.566%Great Point Partners LLCSold 16,295 shares on 8/14/2024Ownership: 3.929%HighVista Strategies LLCSold 8,253 shares on 8/14/2024Ownership: 0.079%Sandia Investment Management LPSold 2,871 shares on 8/14/2024Ownership: 0.012%Cubist Systematic Strategies LLCSold 7,995 shares on 8/14/2024Ownership: 0.010%View All Institutional Transactions ABVX Stock Analysis - Frequently Asked Questions How have ABVX shares performed this year? ABIVAX Société Anonyme's stock was trading at $10.70 at the beginning of 2024. Since then, ABVX stock has increased by 15.4% and is now trading at $12.35. View the best growth stocks for 2024 here. When did ABIVAX Société Anonyme IPO? ABIVAX Société Anonyme (ABVX) raised $217 million in an initial public offering (IPO) on Friday, October 20th 2023. The company issued 18,699,460 shares at a price of $11.60 per share. Who are ABIVAX Société Anonyme's major shareholders? ABIVAX Société Anonyme's top institutional investors include Great Point Partners LLC (3.93%), Nantahala Capital Management LLC (1.57%), HighVista Strategies LLC (0.08%) and Sandia Investment Management LP (0.01%). How do I buy shares of ABIVAX Société Anonyme? Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABVX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABIVAX Société Anonyme Please log in to your account or sign up in order to add this asset to your watchlist. Share ABIVAX Société Anonyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.